- Companies
- Imperative Care
Imperative Care Valuation, Funding & Investors
Imperative Care is valued at $1.7B as of July 2024.
Last Imperative Care valuation
$1.7B
Series E · Jul 2024
Last Imperative Care funding round
$100M
Undisclosed stage · Mar 2026
Cumulative funding Imperative Care raised
$619M
across 6 funding rounds
Key investors in Imperative Care
Bain Capital
Ally Bridge Group
Rock Springs Capital
D1 Capital Partners
Catalio Capital Management
Ascension Ventures
About Imperative Care
Imperative Care is a medical device company advancing stroke treatment technologies. Its portfolio includes aspiration systems and access catheters designed for rapid thrombectomy and improved patient outcomes. Alameda-headquartered, the firm addresses ischemic stroke intervention needs in hospitals worldwide.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$1.7B (Jul 2024)
Sectors
Imperative Care Valuation
Imperative Care is currently valued at $1.7B, based on its Series E in July 2024. Read the announcement ↗
The $150M round was led by Ally Bridge Group, with participation from Montreux Equity Partners, Innovatus Capital Partners, HealthCor Family Office, Catalio Capital Management, Rock Springs Capital and 5 other investors.
Imperative Care's valuation has grown 1.2x from $1.4B at its Series D in July 2021 to $1.7B in July 2024, across 2 priced rounds.
Imperative Care valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jul 2024 | Series E | $1.7B |
| Jul 2021 | Series D | $1.4B |
Imperative Care Funding History
Imperative Care has raised a total of $619M across 6 funding rounds.
Imperative Care's first fundraising round was a $3M seed round in April 2017. The most recent completed round was a $100M undisclosed-stage round in March 2026.
Imperative Care funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2026 | Undisclosed stage | Elevage Medical Technologies (lead); Perceptive Advisors (lead); Longaeva Partners; Catalio Capital Management; Brown Advisory US Smaller; Bain Capital; Ally Bridge Group | $100M | - | Imperative Care raised a $100 million convertible note financing, announced on 17 March 2026 as oversubscribed and closed. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors, together with existing investor Catalio Capital Management. New investors Longaeva Partners and Brown Advisory also took part, and existing investors including Ally Bridge Group and Bain Capital Life Sciences supported the round. Evan Melrose, CEO of Elevage Medical Technologies, joined the board. Proceeds fund commercialisation of the stroke and vascular thrombectomy portfolios, new product development including the Telos robotic platform, and clinical evidence generation. BofA Securities and J.P. Morgan were joint placement agents. Imperative Care is a commercial-stage medical technology company based in Campbell, California, focused on treatments for thromboembolic disease. Its products include the Zoom Stroke System, the Symphony Thrombectomy System and the Prodigy Thrombectomy System, used in more than 78,000 procedures. |
| Jul 2024 | Series E | Ally Bridge Group (lead); Montreux Equity Partners; Innovatus Capital Partners; HealthCor Family Office; Catalio Capital Management; Rock Springs Capital; D1 Capital Partners; Intai Technology; Bain Capital; Pura Vida Investments; AMED Ventures | $150M | $1.7B | Imperative Care is a medical technology company developing devices and digital health solutions for stroke and vascular thrombectomy, including the Zoom aspiration system for clot removal and the Kandu Health platform for remote patient monitoring post-stroke. The company announced an oversubscribed Series E financing round on July 25, 2024, led by Ally Bridge Group, with participation from existing investors AMED Ventures, Bain Capital Life Sciences, D1 Capital Partners, Innovatus Capital Partners, Pura Vida Investments, and Rock Springs Capital, plus new investors Catalio Capital Management, HealthCor Family Office, Intai Technology, and Montreux Equity Partners. Sources describe the round as potentially up to $150 million across multiple tranches (E-1 $75M, E-2 $50M, E-3 $25M) or $72.63M in aggregate, at a post-money valuation of $1.66 billion and $6.87 price per share. Proceeds are intended to fuel hypergrowth, support commercialization of stroke and vascular thrombectomy portfolios, invest in next-generation products like the Telos robotic platform, and generate clinical evidence on patient outcomes. The financing reflects strong investor confidence in Imperative Care's momentum in addressing treatment gaps for thromboembolic diseases. Shacey Petrovic was appointed vice chair of the board alongside the announcement. Previously, Imperative Care raised $260 million in a Series D round on July 15, 2021, at a $1.35 billion post-money valuation with overlapping investors including Ally Bridge Group. A separate $100 million convertible note financing was closed more recently, co-led by Elevage Medical Technologies and Perceptive Advisors with Catalio Capital Management, supported by Ally Bridge Group and Bain Capital Life Sciences, to further commercialization and R&D. |
| Jul 2021 | Series D | D1 Capital Partners (lead); Innovatus Capital Partners; Delos Capital; HealthCor Partners; Rock Springs Capital; Bain Capital; Ascension Ventures; AMED Ventures; Ally Bridge Group | $260M | $1.4B | Imperative Care, Inc. is a medical technology company focused on advancing treatments for thromboembolic diseases, particularly in stroke care and peripheral vascular disease. The company develops innovative devices for stroke intervention and thrombectomy, with two FDA-cleared devices at the time of the Series D round. In July 2021, Imperative Care closed a $260 million Series D financing round led by D1 Capital Partners, with participation from new investors HealthCor Investments and Innovatus Capital Partners, as well as existing investors including Ally Bridge Group, AMED Ventures (Amed Ventures), Ascension Ventures, Bain Capital Life Sciences, Delos Capital, and Rock Springs Capital. By this round, Imperative Care had raised over $300 million since its 2015 founding. Proceeds were earmarked to advance marketing and development of Imperative Care's stroke care technologies, form strategic wholly-owned development subsidiaries, and support the integration of Truvic Medical, a peripheral thrombectomy firm acquired in a stock-for-stock deal using round proceeds. Truvic's technologies target peripheral vascular disease treatment, expanding Imperative Care's portfolio beyond stroke into synergistic areas. Post-Series D, Imperative Care continued growth with later rounds including a $100 million convertible note and Series E financings in 2024 totaling around $150 million at a $1.66 billion valuation, reflecting ongoing investor support from many of the same backers plus new ones like Catalio Capital Management. The company positioned itself to build a portfolio of stroke and vascular technologies, including next-generation products like the Telos robotic platform. |
| Dec 2019 | Series C | Ally Bridge Group (lead); Bain Capital (lead); Delos Capital; Incept LLC; Rock Springs Capital; Ascension Ventures | $85M | - | Imperative Care, Inc. is a medical technology company developing neurovascular devices for treating ischemic and hemorrhagic strokes, including the ZOOM Aspiration System and Large Distal Platform access catheters, both FDA-cleared by 2019. The company completed the initial closing of an $85 million Series C financing around October/December 2019, co-led by Ally Bridge Group and Bain Capital Life Sciences, with participation from existing investors Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept LLC. Frank Yu of Ally Bridge and Andrew Hack, M.D., Ph.D., of Bain Capital joined the board. Proceeds supported the commercial launch of Imperative Care's stroke treatment portfolio, emphasizing clinical evidence and pipeline development. The financing occurred at a key growth stage following FDA clearances, positioning the company to expand market access for its innovative aspiration and access technologies. Subsequent rounds included a Series D of $260 million in July 2021 and later Series E (up to $150 million, initial close led by Ally Bridge Group) and $100 million convertible note financings. |
| Jul 2017 | Undisclosed stage | - | $21M | - | Imperative Care is a medical technology company developing neurovascular devices for treating ischemic and hemorrhagic strokes, including the ZOOM Aspiration System and Large Distal Platform access catheters. The company received FDA 510(k) clearance for these products around the time of its earlier funding rounds. Subsequent rounds included a Series C financing with an initial closing of $85 million announced around November 2019, co-led by Ally Bridge Group and Bain Capital Life Sciences, with participation from existing investors like Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept LLC. This supported the commercial launch of its stroke treatment portfolio. Later financings encompassed a Series D of $260 million in July 2021 at a post-money valuation of $1.35 billion, and multiple Series E tranches in 2024 totaling around $150 million at $1.66 billion post-money valuation, involving investors such as Ally Bridge Group, Bain Capital Life Sciences, D1 Capital Partners, and others. A $100 million convertible note financing was also announced, co-led by Elevage Medical Technologies and Perceptive Advisors, with participation from Catalio Capital Management, Longaeva Partners, Brown Advisory, Ally Bridge Group, and Bain Capital Life Sciences, to fund commercialization of stroke and vascular thrombectomy products, next-generation development like the Telos robotic platform, and clinical evidence generation. |
| Apr 2017 | Seed | - | $3M | - | Imperative Care, a medical technology company spun off from Incept in 2015, develops devices for stroke treatment, including access catheters for brain blood vessels and clot removal systems for ischemic strokes. Regulatory filings indicate it received $3 million in funding in April 2017 from undisclosed investors, followed by $21 million three months later. These early rounds contributed to the company's growth ahead of larger financings like the $85 million Series C in February 2020 and $260 million Series D in July 2021. |
Who has invested in Imperative Care?
19 investors have backed Imperative Care across its funding rounds, including Bain Capital, Ally Bridge Group, Rock Springs Capital, D1 Capital Partners, Catalio Capital Management and Ascension Ventures.
Lead investors include Elevage Medical Technologies, Perceptive Advisors, Ally Bridge Group, D1 Capital Partners and Bain Capital.
Imperative Care Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Dec 2019 | ||
| 4 | Lead | Dec 2019 | ||
| 3 | Participant | Dec 2019 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Participant | Dec 2019 | ||
| 2 | Participant | Jul 2024 | ||
| 2 | Lead | Jul 2021 | ||
| 2 | Participant | Dec 2019 | ||
| 2 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2024 | ||
| 1 | Participant | Jul 2024 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Dec 2019 | ||
This data is available for Pro users. Sign up to see all 19 Imperative Care investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialImperative Care Competitors
Imperative Care competitors include listed companies like Molbio Diagnostics, Butterfly Network, Immunocore Holdings and Poly Medicure, and private ones like Rakuten Medical and MicroPort NeuroTech.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $150M | $34M | $1.6B | - | ||
| Publicly listed | $98M | ($73M) | $1.7B | 13.2x | ||
| Private | - | - | $1.7B | - | ||
| Publicly listed | $400M | ($20M) | $1.6B | 2.6x | ||
| Publicly listed | $198M | $59M | $1.7B | 7.4x | ||
| Private | $56M | - | $1.8B | 31.3x |
Imperative Care Public Comps
Imperative Care is still privately-owned, but its public comps include Rigaku, Medartis, Cofoe Medical, Molbio Diagnostics, Fukuda Denshi, Shanghai MicroPort, Vitrolife, Butterfly Network, Immunocore Holdings and Sinocare.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $595M | $138M | 3.2x | 3.0x | 13.8x | 12.4x | |||
| $330M | $54M | 5.7x | 4.7x | 34.8x | 25.6x | |||
| $508M | $90M | 2.8x | 2.2x | 15.6x | 14.1x | |||
| $150M | $34M | 11.1x | - | 49.0x | - | |||
| $883M | $246M | 1.4x | 1.4x | 4.9x | - | |||
| $203M | $109M | 6.5x | 5.9x | 12.1x | 11.2x | |||
| $350M | ($449M) | 4.9x | 4.8x | (3.8x) | 15.1x | |||
| $98M | ($73M) | 16.4x | 13.2x | (21.8x) | (104.5x) | |||
This data is available for Pro users. Sign up to see all Imperative Care competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Imperative Care
| When was Imperative Care founded? | Imperative Care was founded in 2015. |
| Where is Imperative Care headquartered? | Imperative Care is headquartered in San Jose, CA, United States. |
| Is Imperative Care publicly listed? | No, Imperative Care is a private, VC-backed company. |
| What is Imperative Care's valuation? | Imperative Care was last valued at $1.7B in its Series E in July 2024. |
| How much funding has Imperative Care raised? | Imperative Care has raised $619M across 6 funding rounds. |
| What was Imperative Care's last funding round? | Imperative Care's last funding round was a $100M undisclosed-stage round in March 2026, led by Elevage Medical Technologies and Perceptive Advisors. |
| Who are Imperative Care's investors? | Imperative Care's investors include Bain Capital, Ally Bridge Group, Rock Springs Capital, Innovatus Capital Partners, Delos Capital, Catalio Capital Management, D1 Capital Partners, Ascension Ventures, AMED Ventures, Montreux Equity Partners and 9 others. |
| Which companies are comparable to Imperative Care? | Companies comparable to Imperative Care include Molbio Diagnostics, Butterfly Network, Rakuten Medical, Immunocore Holdings, Poly Medicure and MicroPort NeuroTech. |
See companies similar to Imperative Care
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




